Skip to content
Shorla Oncology: A Leader in Innovative Oncology Solutions
  • About Us
    • Executive Team
    • Leadership Team
    • Board of Directors
    • Advisory Team
  • Products
    • TEPYLUTE
    • IMKELDI
    • JYLAMVO
    • Nelarabine Injection
  • Pipeline
  • News
    • Company Updates
    • Media
  • Careers
  • Contact

News

Photo

Shorla Oncology – Q&A with Tracy Woody

March 7th 2022February 25th 2021

Read More

Logo

Diversity & inclusion in Pharma

April 19th 2021February 11th 2021

Read More

Logo

Making It Work: Irish firm to launch children’s cancer treatment in US

April 19th 2021December 14th 2020

Read More

Logo

Female entrepreneurs can help level the start-up playing field

April 19th 2021November 22nd 2020

Read More

Logo

Sharon Cunningham : Six Keys to Beating the Odds and Achieving Startup Success

April 19th 2021November 12th 2020

Read More

Photo

John Moloney and Tracy Woody announced as non-executive Board members

March 7th 2022November 10th 2020

Read More

Logo

How an executive MBA was the catalyst for a pharma start-up

April 19th 2021October 25th 2020

Read More

Photo

Shorla speak with Dr. Scott Gottlieb, 23rd FDA Commissioner

March 7th 2022October 9th 2020

Read More

Shorla Oncology

SH-110 Successful FDA Pre-IND Meeting

March 7th 2022October 2nd 2020

Read More

Older posts
Newer posts
Page1 … Page15 Page16 Page17 … Page19
Logo

IRELAND HQ:
Questum Acceleration Center,
Ballingarrane Science & Technology Park,
Clonmel, Co. Tipperary,
E91 V329, Ireland

Shorla Pharma Ltd trading as Shorla Oncology®

All trademarks are the property of their respective owners.

US OFFICE:
245 Main St.,
2nd floor,
Cambridge,
MA 02142, USA

SITEMAP

PRIVACY POLICY

CALIFORNIA COMPLIANCE PROGRAM DECLARATION

Company number: 618033
©SHORLA ONCOLOGY® 2025

© 2025 Shorla Oncology: A Leader in Innovative Oncology Solutions • Built with GeneratePress
  • About Us
    • Executive Team
    • Leadership Team
    • Board of Directors
    • Advisory Team
  • Products
    • TEPYLUTE
    • IMKELDI
    • JYLAMVO
    • Nelarabine Injection
  • Pipeline
  • News
    • Company Updates
    • Media
  • Careers
  • Contact

Now approved for use in Pediatrics

  • Treatment of pediatric patients with polyarticular juvenile idiopathic arthritis (pJIA).
  • Treatment of pediatric patients with acute lymphoblastic leukemia (ALL) as part of a combination chemotherapy maintenance regimen.

Please click here for the full Prescribing information, including Boxed Warning regarding embryo-fetal toxicity, hypersensitivity reactions, and severe adverse reactions.